Live Breaking News & Updates on Benjamin ansell

Stay informed with the latest breaking news from Benjamin ansell on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Benjamin ansell and stay connected to the pulse of your community

Mounjaro Patients Show Hugely Improved Blood Pressure

A rival to trendy weight loss drug semaglutide has been shown to drastically improve people's blood pressure after 36 weeks of taking the medication, according to a new study published in the journal Hypertension. The medication is called tirzepatide, developed by the big pharmaceutical company Eli Lilly, which the Federal Drug Administration approved a few […]

New-york , United-states , California , Eli-lilly , Benjamin-ansell , Los-angeles , New-york-times , Novo-nordisk , University-of-california , Drug-administration , Federal-drug-administration , Lood-pressure

UCLA in the News March 6, 2023

Highlights from the New York Times, CNN, NBC News and others.

Alabama , United-states , New-york , Japan , Iran , China , California , Columbia-university , Russia , Los-angeles , San-francisco , America

Nexletol may reduce high cholesterol in those who can't tolerate statins

Not everyone can tolerate statins to reduce their high cholesterol, but now a new study finds the medication bempedoic acid (Nexletol) reduced the combined rate of bad cardiovascular events by 13%.

New-york , United-states , California , Ohio , Cleveland , Los-angeles , Benjamin-ansell , Steven-nissen , Harlan-krumholz , University-of-california , New-york-times , Us-centers-for-disease

A Statin Alternative Joins Drugs That Can Reduce Heart Attack Risk

Bempedoic acid lowers cholesterol, and a study found a modest effect on cardiac illness. But whether patients are any more willing to take it remains to be seen, experts said.

United-states , Americans , John-alexander , Michael-davidson , Benjamin-ansell , Steven-nissen , Harlan-krumholz , American-college-of-cardiology , Drug-administration , University-of-chicago-pritzker-school-medicine , New-england-journal , American-college